Publications by authors named "J Ahlgren"
Background: Although precision oncology has rapidly been developed in recent years, its real-world impact and challenges in healthcare implementation remain underexplored. Through a meta-analysis of real-world evidence (RWE), we aimed at investigating the applicability and clinical impact of comprehensive cancer genome profiling (CGP) in cancer patients with metastatic solid tumors.
Methods: We systematically searched Medline, Embase, and Web of Science for RWE studies on CGP and matched therapies in metastatic solid tumors (publication period: 2012-2023).
Background: This prospective cohort study aimed to assess whether postoperative radiotherapy could safely be omitted in women ≥ 65 years with low-risk, estrogen receptor (ER)-positive T1N0 breast cancer treated with breast-conserving surgery and adjuvant endocrine therapy.
Methods: Eligible patients were women ≥ 65 years with unifocal, non-lobular, grade 1 or 2, ER-positive, pT1N0 breast cancer treated with breast-conserving surgery and endocrine therapy for five years. Patients were followed up with mammography at least annually for 10 years.
Background: Assessment of Rehabilitation Needs Checklist (ARNC), has been developed to assess rehabilitation need in cancer patients and is recommended by the Confederation of Regional Cancer Centres in Sweden, known as Hälsoskattningen. The aim of the study was to test the reliability and validity of the ARNC, mainly by comparing it with the Distress thermometer and EORTC QLQ-C30.
Methodology: A sample of 993 persons identified in the Swedish cancer register.
Purpose: To examine health-related quality of life (HRQoL) and supportive care needs among young adult (YA) cancer survivors up to 3 years post-diagnosis.
Methods: A national cohort of individuals diagnosed at 18-39 years with breast, cervical, ovarian, or testicular cancer, lymphoma or brain tumor was approached with surveys at 1.5 (n = 1010, response rate 67%) and 3 (n = 722) years post-diagnosis.
Article Synopsis
- A noninferiority trial was conducted to assess if omitting completion axillary-lymph-node dissection is as effective as performing it in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases.
- A total of 2,766 patients were enrolled, with 1,335 assigned to sentinel-node biopsy only and 1,205 to the dissection group, with a median follow-up of 46.8 months.
- The results showed a 5-year recurrence-free survival rate of 89.7% for the sentinel-node biopsy-only group, suggesting that this approach may not significantly compromise patient outcomes compared to the traditional method.